Terns Pharmaceuticals, Inc. (TERN)
- Previous Close
2.8800 - Open
2.8800 - Bid 2.1200 x 200
- Ask 3.6300 x 200
- Day's Range
2.8115 - 3.0000 - 52 Week Range
1.8650 - 11.4000 - Volume
496,934 - Avg. Volume
1,333,078 - Market Cap (intraday)
259.71M - Beta (5Y Monthly) -0.14
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.06
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
www.ternspharma.comRecent News: TERN
View MorePerformance Overview: TERN
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TERN
View MoreValuation Measures
Market Cap
250.54M
Enterprise Value
-106.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.13%
Return on Equity (ttm)
-29.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-88.85M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
358.16M
Total Debt/Equity (mrq)
0.39%
Levered Free Cash Flow (ttm)
-43.26M